hsg summary of accomplishments, page-12

Hi PJ,

I think it is safe to assume that we are all a bit disappointed in the lack of timely forthcoming information.
Other than scan data and actual blood samples and eye exams the rest can prove to be troublesome. For information to be assimilated, there cannot be a great divide between continental testing locations IE US and Aus. I truly believe this is the main hold up but do not necessarily consider it negative.
If many of the mouse model results translate over to the cases in the HD trial, I think we will be in pretty good shape.
The biggest draw back I see is the length of the trial and perhaps dosage regime.
I believe the HD data will show that PBT2 is beneficial especially coupled with the AD data.
Could they intentionally be holding back on the HD final assessment because of this very nature?
If so and then coupled with the AD results the outcome looks much more favorable then I for one would want Prana to continue on with their plan.
I still agree however, that it is far better to deal with actual information rather than speculation at this stage. No matter what, we can safely expect information within weeks!